Site icon Fact.MR Blog

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Is Projected To Be Valued At US$ 620.5 Million In 2022

admin
images 34

The global idiopathic thrombocytopenic purpura therapeutics market was valued at US$ 587.0 Million in 2021, and is projected to be valued at US$ 620.5 Million in 2022. During the 2022-2032 period of assessment, demand is expected to rise at a 5.0% value CAGR, likely to reach US$ 1.0 Billion by the end of the said forecast period.

Overall, the idiopathic thrombocytopenic purpura therapeutics landscape is poised to yield an absolute dollar opportunity worth US$ 390.9 Million until 2032. Sales of Idiopathic Thrombocytopenic Purpura Therapeutics will continue to flourish, with a documented CAGR of 5.6% from 2015-2021.

Request For Sample Report-  https://www.factmr.com/connectus/sample?flag=S&rep_id=7449

Competitive Landscape

The global market for Idiopathic Thrombocytopenic Purpura Therapeutics is characterized by the presence of multiple vendors, aiming to offer extensive products to consumers. Additionally, key makers are focusing on developing the devices supported by the implementation of stringent government regulations, and are offering solutions tailor-made to suit their business objectives. In addition, the vendors are likely to leverage upgradation and product differentiation to gain an edge over other competitors in the market.
  • In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.
  • In April 2018, U.S Food and Drug Administration (FDA) approved the therapeutic use of TAVALISSE developed by Rigel Pharmaceuticals, Inc. as the second line of treatment for ITP.
  • In March 2018, Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong.

Key Segments Covered in the Idiopathic Thrombocytopenic Purpura Therapeutics Industry Report

  • Idiopathic Thrombocytopenic Purpura Therapeutics Market by Product Type :

    • Corticosteroids-based Idiopathic Thrombocytopenic Purpura Therapeutics
    • Intravenous Immunoglobulins-based Idiopathic Thrombocytopenic Purpura Therapeutics
    • Anti-D Immunoglobulin-based Idiopathic Thrombocytopenic Purpura Therapeutics
    • Thrombopoietin Receptor Agonists (TPO-RA) based Idiopathic Thrombocytopenic Purpura
    • Other Idiopathic Thrombocytopenic Purpura Therapeutic Products

  • Idiopathic Thrombocytopenic Purpura Therapeutics Market by Distribution Channel :

    • Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Drug Stores
    • Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Retail Pharmacies
    • Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Other Distribution Channels

  • Idiopathic Thrombocytopenic Purpura Therapeutics Market by Treatment Type :

    • Oral Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics
      • Prednisone
      • Rituximab
      • Azathioprine
      • Eltrombopag
    • Splenectomy-based Idiopathic Thrombocytopenic Purpura Therapeutics
      • Intravenous Immunoglobulin (IVIG)
      • Anti-D Immunoglobulin
      • Thrombopoietin Receptor Agonists

  • Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region :

    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

 

Exit mobile version